112 related articles for article (PubMed ID: 1300751)
1. [The humoral immunity indices of patients with malignant skin melanoma using the viral immunomodulator rigvir].
Glinkina LS; Heisele OG; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):534-40. PubMed ID: 1300751
[TBL] [Abstract][Full Text] [Related]
2. [The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator rigvir].
Glinkina LS; Bruvere RZh; Venskus DR; Garklava RR; Muceniece AJ
Vopr Onkol; 1992; 38(5):540-7. PubMed ID: 1300752
[TBL] [Abstract][Full Text] [Related]
3. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Glinkina LS; Bruvere RZh
Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
[TBL] [Abstract][Full Text] [Related]
4. [Disorders of immune system function and their correction in melanomas with regional metastases].
Labunets IF; Grinevich IuA; Tolstopiatov BA
Vopr Onkol; 1989; 35(4):416-23. PubMed ID: 2728381
[TBL] [Abstract][Full Text] [Related]
5. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
Doniņa S; Strēle I; Proboka G; Auziņš J; Alberts P; Jonsson B; Venskus D; Muceniece A
Melanoma Res; 2015 Oct; 25(5):421-6. PubMed ID: 26193376
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
7. Vaccination and melanoma risk.
Pfahlberg A; Botev IN; Kölmel KF; Gefeller O
Int J Cancer; 2002 Nov; 102(1):96-7. PubMed ID: 12353240
[No Abstract] [Full Text] [Related]
8. [A comparison of the morphofunctional characteristics of the peripheral blood lymphocytes and the immune status of patients with malignant melanoma of the skin].
Naleskina LA; Ganina KP; Labunets IF; Grinevich IuA; Abramenko VA
Tsitol Genet; 1996; 30(5):16-22. PubMed ID: 9026985
[TBL] [Abstract][Full Text] [Related]
9. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
Killock D
Nat Rev Clin Oncol; 2015 Aug; 12(8):438. PubMed ID: 26077044
[No Abstract] [Full Text] [Related]
10. [Nonspecific active stimulation of the immune system in the combined treatment of rectal cancer].
Kikot' VA; Dziubko NIa
Vrach Delo; 1989 Jul; (7):46-8. PubMed ID: 2800496
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
12. The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts P; Tilgase A; Rasa A; Bandere K; Venskus D
Eur J Pharmacol; 2018 Oct; 837():117-126. PubMed ID: 30179611
[TBL] [Abstract][Full Text] [Related]
13. [Dynamics of the humoral immunity indices in patients with subacute brucellosis being treated with levamisole].
Mukovozova LA
Zh Mikrobiol Epidemiol Immunobiol; 1987 Jul; (7):56-9. PubMed ID: 3499730
[TBL] [Abstract][Full Text] [Related]
14. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
15. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.
Saul L; Ilieva KM; Bax HJ; Karagiannis P; Correa I; Rodriguez-Hernandez I; Josephs DH; Tosi I; Egbuniwe IU; Lombardi S; Crescioli S; Hobbs C; Villanova F; Cheung A; Geh JL; Healy C; Harries M; Sanz-Moreno V; Fear DJ; Spicer JF; Lacy KE; Nestle FO; Karagiannis SN
Sci Rep; 2016 Jul; 6():29736. PubMed ID: 27411958
[TBL] [Abstract][Full Text] [Related]
16. [Immune status of patients with malignant melanoma during combined therapy including local ultra-high frequency hyperthermia].
Risina DIa; Zhakov IG; Fradkin SZ; Zhabrid EA
Vopr Onkol; 1989; 35(12):1437-40. PubMed ID: 2532801
[TBL] [Abstract][Full Text] [Related]
17. [Indices of cellular and humoral immunity in patients with disseminated sclerosis being treated with immunomodulators].
Zapadniuk BV; Kravets AS; Iarosh AA; Shurinok LA
Vrach Delo; 1988 Aug; (8):84-6. PubMed ID: 3206892
[No Abstract] [Full Text] [Related]
18. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.
Alberts P; Olmane E; Brokāne L; Krastiņa Z; Romanovska M; Kupčs K; Isajevs S; Proboka G; Erdmanis R; Nazarovs J; Venskus D
APMIS; 2016 Oct; 124(10):896-904. PubMed ID: 27457663
[TBL] [Abstract][Full Text] [Related]
20. Autoimmunity and immunotherapy for cancer.
Koon H; Atkins M
N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
